Intellia Therapeutics - NTLA Competitors

Intellia Therapeutics (NASDAQ:NTLA) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends.

Does the media refer more to NTLA or NEOG?

In the previous week, Intellia Therapeutics had 4 more articles in the media than Neogen. MarketBeat recorded 11 mentions for Intellia Therapeutics and 7 mentions for Neogen. Intellia Therapeutics' average media sentiment score of 0.63 beat Neogen's score of 0.30 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is NTLA or NEOG more profitable?

Neogen has a net margin of -2.57% compared to Intellia Therapeutics' net margin of -909.78%. Neogen's return on equity of 5.56% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-909.78%	-48.70%	-38.57%
Neogen	-2.57%	5.56%	4.26%

Which has more volatility and risk, NTLA or NEOG?

Intellia Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Neogen has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Do analysts rate NTLA or NEOG?

Intellia Therapeutics presently has a consensus price target of $87.18, suggesting a potential upside of 140.49%. Neogen has a consensus price target of $20.00, suggesting a potential upside of 14.88%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.83
Neogen	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community believe in NTLA or NEOG?

Intellia Therapeutics received 74 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 70.09% of users gave Intellia Therapeutics an outperform vote while only 58.54% of users gave Neogen an outperform vote.

Company	Underperform	Outperform
Intellia Therapeutics	Outperform Votes 403 70.09%	Underperform Votes 172 29.91%
Neogen	Outperform Votes 329 58.54%	Underperform Votes 233 41.46%

Do insiders & institutionals have more ownership in NTLA or NEOG?

85.6% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Neogen shares are held by institutional investors. 2.6% of Intellia Therapeutics shares are held by company insiders. Comparatively, 0.7% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, NTLA or NEOG?

Neogen has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$52.12 million	61.22	-$474.19 million	-$6.18	-5.87
Neogen	$527.16 million	7.14	$48.31 million	$0.05	348.20

Summary

Intellia Therapeutics beats Neogen on 10 of the 18 factors compared between the two stocks.